Caris Life Sciences, a next-generation AI TechBio company and precision medicine pioneer, entered into an agreement with Moderna in support of Moderna’s oncology and novel therapeutics initiatives. Through the multi-year agreement, Moderna will leverage Caris’ vast library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna’s ...